{"url_path":"/sec/nxtc/8-k/2026-07-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1661059/0001104659-26-083326-index.html","accession_number":"0001104659-26-083326","cik":"0001661059","ticker":"NXTC","issuer_name":"NextCure, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1661059/0001104659-26-083326-index.html","primary_entity_key":"0001661059","primary_entity_name":"NextCure, Inc."},"word_count":134,"has_tables":true,"body_markdown":"** **\n\n**Item 7.01****Regulation FD Disclosure**\n\n \n\nOn July 14, 2026, NextCure\nand Avere issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1\nto this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced\nin the press release is not incorporated herein by reference.\n\n \n\nThe information in this Item\n7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor\nshall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth\nby specific reference in such filing."}